GenSight Biologics SA 2025 IR
The report outlines GenSight Biologics S.A.'s operational and financial progress for the fiscal year ended December 31, 2025. Key highlights include the receipt of Compassionate Use Authorization (AAC) for its lead gene therapy GS010/LUMEVOQ® in France and early access approvals in Israel and the United States. The company successfully transferred its upstream manufacturing process to Catalent and completed several private placements totaling approximately €14 million in 2025. However, GenSight continues to face material uncertainty regarding its ability to continue as a going concern, requiring additional funding to initiate its planned Phase III RECOVER clinical trial.
Company: GenSight Biologics SA
Sector: Professional & technical services
Country: France
Year: 2025
Type: IR
Pages: 366
Back to company
GenSight Biologics SA
Universal Registration Document
The report outlines GenSight Biologics S.A.'s operational and financial progress for the fiscal year ended December 31, 2025. Key highlights include the receipt of Compassionate Use Authorization (AAC) for its lead gene therapy GS010/LUMEVOQ® in France and early access approvals in Israel and the United States. The company successfully transferred its upstream manufacturing process to Catalent and completed several private placements totaling approximately €14 million in 2025. However, GenSight continues to face material uncertainty regarding its ability to continue as a going concern, requiring additional funding to initiate its planned Phase III RECOVER clinical trial.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Workplace Fatalities
Employees